JLABS Ready for take-off - Canadian Entrepreneurs in Life Science (CELS)-2017-05-18

Event Information
Event Name: 
JLABS Ready for take-off - Canadian Entrepreneurs in Life Science (CELS)
Event Date: 
05/18/2017 - 2:00pm
Event Location: 
JLABS @ SSF, 329 Oyster Point Blvd - 3rd Floor, South San Francisco, California
Event Details
Event Type: 
Panel Discussions
Event Details: 

JLABS, Thursday Afternoon, May 18, 2017

Topic: “Ready for take-off - Canadian Entrepreneurs in Life Science (CELS)”
Speakers: Melinda Richter | Head of JLABS, Johnson & Johnson Innovation read bio»
Mike Powell | General Partner, Sofinnova Ventures; Cedric Bisson | Partner, Teralys Capital; Speaker to be announced | Innovation, Science & Economic Development (ISED)
Date and Time: Thursday, May 18, 2017 from 2:00 PM to 4:30 PM (PDT)
Agenda:
2:00 PM | Registration and Networking
2:30 PM | CELS Introduction
2:45 PM | Panel
3:30 PM | Q&A
3:45 PM | Networking and light refreshments
4:30 PM | Program Close
Location: JLABS @ SSF, 329 Oyster Point Blvd - 3rd Floor, South San Francisco, California

Register at https://www.eventbrite.com/e/ready-for-take-off-canadian-entrepreneurs-i...

Event Details
In cooperation with the Consulate General of Canada, a not for profit association has been formed to tap into the unique talent in the Bay Area to help Canadian Life Science Start-ups reach their potential. The association called the, Canadian Entrepreneurs in Life Science - San Francisco Chapter (CELS-SFO), will collectively support Canadian Life Science innovators/entrepreneurs through mentorship, collaboration and access to expertise and investment.

The goal is to connect the unique Life Science talent of the Bay Area with high potential Canadian-based Life Science Start-ups. The CELS-SFO will focus on three core ingredients: Connections, Community and Capital.

The launch event will feature a panel discussion, "Canada's Life Science Innovation Program - The Opportunity", with distinguished guests representing industry and government. The panel will share their unique knowledge of the needs, opportunities and strengths of both the Canadian and Bay Area life science ecosystems.

Further, CELS-SFO is building its community and looking for your time and input to move Life Science innovations forward on the path to success. The CELS-SFO Community spans the Bay Area, Canada and beyond.

Who should attend:
All Life Science professionals interested in high potential Canadian Life Science companies.

CELSMeet the CELS - SFO leadership team:
Richard Ayllon | Co-Founder, Theravent, Inc.
Hatim Charaibi | Co-Founder & Managing Director, SPIRE Bioventures
Joanne Fedeyko | CEO, Connection Silicon Valley
Rob Hopfner | Managing Director, Bay City Capital
Catherine Love | Director, Capital Services, MaRS Discovery District
Dion Madsen | Senior Managing Partner, BDC Healthcare Venture Fund
Matt Pasiuk | Trade Commissioner - Life Sciences, Consulate General of Canada, San Francisco
James Viola | Innovation Activation Specialist, Johnson & Johnson Innovation, JLABS

Speakers' Biographies:

Melinda Richter | Head, Johnson & Johnson Innovation, JLABS
As Head of Johnson & Johnson Innovation, JLABS, Melinda fosters the Johnson & Johnson Family of Companies external R&D engine and supports the innovation community by creating capital-efficient commercialization models that give early stage companies a big company advantage. By providing infrastructure, services, educational programs and networks in global hotspots, JLABS is the best place to start a company working in healthcare, with a specific emphasis on Johnson & Johnson's sectors: consumer, medical device and pharmaceuticals. Prior to joining JLABS, Melinda was Founder and CEO of Prescience International, an award-winning firm dedicated to accelerating research to the patient. Melinda founded Prescience after she had a medical emergency that left her questioning the efficiency and efficacy of the healthcare system. With the tenacity and resolve of a patient looking for a better solution, she set-out to create a better model, which now forms the basis for JLABS' operational infrastructure. Prior to starting Prescience, Melinda held posts across a variety of functional areas with a global corporation, Nortel Networks, in locations such as Research Triangle Park, New York, Toronto, London, Hong Kong and Beijing before arriving in San Francisco. She also started, raised capital and did large corporate deals for several companies in both the life science and technology space. She holds a Bachelor of Commerce from the University of Saskatchewan in Canada and an MBA from INSEAD in France. Melinda is an active board member and Treasurer of the California LifeSciences Association (CLSA).
^ Back to speakers' list ^

Mike Powell, Ph.D. | General Partner, Sofinnova Ventures
Mike joined Sofinnova in 1997, and SVP IX ($510M) is his sixth Sofinnova fund. He has 32 years of experience, including 15 years of R&D before venture. Mike has been involved in more than 50 clinical programs, and is the author of 90 publications and books, including a 1,000-page treatise on vaccine design. He was the initial venture investor of: Actelion (ATLN), Intermune (ITMN), Orexigen (OREX), Seattle Genetics (SGEN), Threshold (THLD), and Trius (TSRX) and other public and private companies such as Intellikine (sold to Millennium-Takeda), Mirna and Labrys Biologics (sold to Teva). Mike was the first person in the biotech industry to be honored by the American Association of Pharmaceutical Scientists as an AAPS Fellow. He has also served on the journal editorial boards of Journal of Pharmaceutical Sciences and the Journal of Controlled Release. He has been the Board President of the AIDS Vaccine Advocacy Coalition, as well as advisor to the Institute for One World Health, IAVI, and the Bill and Melinda Gates Foundation. Mike is also Adjunct Associate Professor in the Department of Pharmaceutical Chemistry at the University of Kansas, one of the top US pharmacy schools. Before joining Sofinnova, he was group leader of drug delivery at Genentech. During his tenure there, he and colleagues spun off VaxGen, an AIDS vaccine company. Prior to Genentech, he helped start Cytel as the Director of Product Development. Before this he was Senior Scientist and Project Team Leader at Syntex Research. Mike received his PhD in Chemistry from the University of Toronto and carried out postdoctoral studies in bio-organic chemistry at the University of California as a National Science and Engineering Research Council Scholar.
^ Back to speakers' list ^

Cedric Bisson | Partner, Teralys Capital
Cedric Bisson has extensive experience across Canada, Europe and the USA creating, building and advising businesses in biopharmaceuticals, healthcare and the innovation sector in general. He is passionate about growing Canada as a premier environment for innovation, and during his career has structured over $3 B in transactions in funds and companies. Mr. Bisson is currently partner at Teralys Capital where he focuses on healthcare and life sciences investments, as well as growth opportunities. Teralys Capital (www.teralyscapital.com) is Canada's largest innovation-focused investor, financing private funds in IT, life sciences, and clean or industrial innovations, from early stage start-ups to expansion, growth and technology buy-outs. He was previously managing partner for life sciences at iNovia Capital(www.inovia.vc) in Montreal, Calgary and the USA, a private venture capital firm aimed at entrepreneurship and company building, during which he also created MSBi Valorisation (now Allgo, www.aligo.ca/en/), a seed technology transfer and investor firm focused principally on McGill University. Prior to this, he spent close to a decade internationally as associate principal at McKinsey & Company (www.mckinsey.com), a management consulting firm, where he was a leader in the biopharma, healthcare and innovation practices in New York City, Paris, Montreal, and Toronto. Mr. Bisson obtained a M.D. degree from McGill University and a J.D. (law) degree from Universite de Montreal. He still actively engages globally with various government and private entities on innovation and related public policy matters, most notably Grand Challenges Canada (www.grandchallenges.ca), a Toronto organization dedicated to supporting bold ideas with big impact in global health, as well as Vancouver-based Accel-Rx (http://www.accel-rx.com), Canada's national health sciences accelerator.